FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level

THOUSAND OAKS, Calif., Dec. 20, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news